Premium
Synthesis and Antiviral Activity of New Substituted Methyl [2‐(arylmethylene‐hydrazino)‐4‐oxo‐thiazolidin‐5‐ylidene]acetates
Author(s) -
Saeed Aamer,
AlMasoudi Najim A.,
Latif Muhammad
Publication year - 2013
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.201300057
Subject(s) - chemistry , replicon , solvent , hepatitis c virus , in vitro , stereochemistry , human immunodeficiency virus (hiv) , virus , combinatorial chemistry , medicinal chemistry , organic chemistry , biochemistry , virology , biology , dna , plasmid
A series of new methyl [2‐(arylmethylene‐hydrazono)‐4‐oxo‐thiazolidin‐5‐ylidene]acetates ( 5a – o ) were synthesized via cyclocondensation of thiosemicarbazones ( 3a–o ) with dimethyl but‐2‐ynedioate ( 4 ) in good yields under solvent‐free conditions. The environmentally friendly solvent‐free protocol overcomes the limitations associated with the customary protracted solution phase synthesis and afforded the title compounds in a few minutes. Compounds 5b – i and 5h – o were evaluated for their antiviral activity against the replication activity of HIV‐1 and HIV‐2 in MT‐4 using the MTT assay. The same compounds were also evaluated in vitro for their selective antiviral activity against hepatitis C virus (HCV) in the Huh 5‐2 replicon system (type 1b, Con1 strain).